Compare First Solar, Inc. (FSLR) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? First Solar, Inc. trades at $177.86 (market cap $19.22B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 3.1× First Solar, Inc.'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| FSLR | TAK | |
|---|---|---|
Market Cap | $19.22B | $58.74B |
Volume | 2,067,793 | 3,110,994 |
Sector | Energy | Health |
52-Week High | $318.30 | $19.05 |
52-Week Low | $172.11 | $13.23 |
Typical Hold Time | 76 Days | 1 Days |
Enterprise Value | $17.69B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $177.82, down 1.28% on the day, amid a bearish technical signal and recent sector-wide pressures. The stock shows strong fundamentals with a P/E of 11.03, net income margin of 32.47%, and robust cash flow from operations of $2.06B in 2025. Recent news includes a patent infringement lawsuit filed on October 1, 2026, which briefly lifted the stock, while high put option volume on October 3, 2026, indicates investor caution.
FSLR presents a mixed outlook: solid profitability and analyst consensus support a 'Moderate Buy' with a $267.59 price target, but technical weakness and solar sector headwinds from high borrowing costs pose near-term risks. The stock's 44.9% decline from its all-time high highlights volatility, yet earnings beats in Q1 and Q2 2026 underscore operational strength.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
